Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination therapy consisting of autologous microfragmented adipose tissue (MFAT) and high-molecular-weight hyaluronic acid (HA) administered via intra-articular injection. MFAT is obtained from the patient's own abdominal fat through liposuction and a mechanical microfragmentation process that preserves the vascular-stromal niche, including mesenchymal stem cells (MSCs) and pericytes. These cells exert anti-inflammatory and regenerative effects through paracrine signaling. Hyaluronic acid acts as a viscosupplement, restoring the rheological properties of the synovial fluid and providing mechanical lubrication and shock absorption. This dual approach is designed to treat symptomatic knee osteoarthritis by combining the biological regenerative potential of adipose-derived cells with the immediate mechanical benefits of HA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on microfragmented adipose tissue + hyaluronic acid.